MDS Sciex

Applied Biosystems Group

February 28, 2005 07:00 ET

Applied Biosystems/MDS SCIEX and BIOCRATES Announce Metabolomics Collaboration


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: MDS SCIEX

TSX SYMBOL: MDS
NYSE SYMBOL: MDZ

AND APPLIED BIOSYSTEMS

NYSE SYMBOL: ABI

FEBRUARY 28, 2005 - 07:00 ET

Applied Biosystems/MDS SCIEX and BIOCRATES Announce
Metabolomics Collaboration

FOSTER CITY, CALIFORNIA--(CCNMatthews - Feb. 28, 2005) -

Collaboration to Focus on Methods and Consumables Development

Applied Biosystems (NYSE:ABI), an Applera Corporation, together with its
partner MDS Sciex, a division of MDS Inc. (TSX:MDS) (NYSE:MDZ), and
BIOCRATES life sciences GmbH, a bio-knowledge provider and developer of
application systems and consumables for life sciences applications,
today announced a new collaborative agreement whereby the companies plan
to develop metabolomics methods, instruments, and applications. Applied
Biosystems is hosting a press conference today at 10:00 a.m. ET to
discuss the collaboration at the Pittsburgh Conference (PITTCON) in
banquet room N220G at the Orange County Convention Center in Orlando,
FL, U.S.A.

Under the agreement, Applied Biosystems/MDS SCIEX will provide BIOCRATES
life sciences with its industry-leading QSTAR® LC/MS/MS System and API
4000™ Q LC/MS/MS system mass spectrometers to develop both
consumables and methods for sample preparation and metabolomics
analysis. Applied Biosystems will distribute any products developed from
the collaboration.

"Procedures in clinical research chemistry and immunology currently
provide researchers with limited biomarkers for diagnosis and treatment
decisions. Mass spectrometric assays should soon be able to detect and
quantitate several hundred, and eventually thousands of metabolites from
the intermediary metabolism, representing a biochemical fingerprint of
the human organism, and reflecting not only genetic pre-disposition, but
also environmental influences, such as nutrition or medication," said
Dr. Klaus Weinberger, Chief Scientific Officer of BIOCRATES life
sciences.

"This collaboration will provide Applied Biosystems/MDS SCIEX with a
unique insight into the needs of the growing metabolomics market and
fits well with Applied Biosystems overall metabolomics strategy to
provide complete solutions to our customers through external
collaboration or internal development projects," said Laura Lauman,
Division President of Proteomics and Small Molecule Business for Applied
Biosystems.

"BIOCRATES life sciences is at the forefront of innovation in
metabolomics technology, and we anticipate this being a very productive
collaboration for markets that we both serve," said Andy Boorn,
President of MDS Sciex.

"Our goal is to deliver, to every scientist, a high-content screening
technology platform for the standardized and systematic quantitative
targeted analysis and direct interpretation of hundreds of annotated
metabolites, simultaneously, from microliter quantities of biological
material," said Dr. Armin Graber, Chief Executive Officer of BIOCRATES
life sciences. "We are pleased to join forces with the Applied
Biosystems/MDS SCIEX joint venture, the market leader in life sciences
and mass spectrometry. We believe this collaboration will support
widespread utilization and commercialization of metabolome information,
thus advancing both clinical diagnostics and the pharmaceutical research
and development process."

About Applera Corporation and Applied Biosystems

Applera Corporation consists of two operating groups. The Applied
Biosystems Group serves the life science industry and research community
by developing and marketing instrument-based systems, consumables,
software, and services. Customers use these tools to analyze nucleic
acids (DNA and RNA), small molecules, and proteins to make scientific
discoveries, develop new pharmaceuticals, and conduct standardized
testing. Applied Biosystems is headquartered in Foster City, CA, and
reported sales of $1.7 billion during fiscal 2004. The Celera Genomics
Group (NYSE:CRA) is engaged principally in the discovery and development
of targeted therapeutics for cancer, autoimmune and inflammatory
diseases. Celera Genomics is leveraging its proteomic, bioinformatic,
and genomic capabilities to identify and validate drug targets, and to
discover and develop small molecule therapeutics. It is also seeking to
advance therapeutic antibody and selected small molecule drug programs
in collaboration with global technology and market leaders. Celera
Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera
Genomics, is focused on discovery, development, and commercialization of
diagnostic products. Information about Applera Corporation, including
reports and other information filed by the company with the Securities
and Exchange Commission, is available at http://www.applera.com, or by
telephoning 800.762.6923. Information about Applied Biosystems is
available at http://www.appliedbiosystems.com/.

About MDS Sciex and MDS Inc.

MDS Sciex is the analytical instrumentation and technology solutions
division of MDS Inc. At MDS Inc., our 9,000 highly skilled people
provide services and products, which enable health sciences
organizations to enhance the well being of people around the world. We
focus on helping discover and test new drugs, assisting doctors to
diagnose and treat patients and preventing the spread of disease. Find
out more about MDS Inc. (TSX: MDS; NYSE: MDZ), at www.mdsintl.com
"http://mdsintl.com" or by calling 1-888-MDS-7222, 24 hours a day.

About BIOCRATES life sciences

BIOCRATES life sciences, a provider of high content metabolome
information and technology, develops application systems and
consumable-based products for diagnostics and pharmaceutical research
and development. The targeted metabolomics analysis platform comprises
fully automated sample preparation procedures and software linked to
mass spectrometry-based analytics. The quantitative metabolite profiling
approach enables routine high-content screening and standardized
wide-spread use of metabolomics technology. Relative quantification is
achieved by reference to a wide range of appropriate internal standards.
Analytes and corresponding metabolites are annotated so as to allow fast
and direct biochemical and biological interpretation. In partnership
with pharmaceutical, biotechnology and nutrition companies, BIOCRATES
life sciences uses its technology to speed drug discovery processes,
reduce late-stage drug attrition due to adverse side effects, discover
new biomarkers and develop early tests for monitoring drug response.
BIOCRATES life sciences' technology is also applied to validate and
prioritize drug targets, identify novel applications for existing drugs
and improve drug safety by analyzing the pharmacological and
toxicological effects of a substance with unprecedented resolution and
sensitivity. Information about BIOCRATES life sciences is available at
http://www.biocrates.at/.

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking. These may
be identified by the use of forward-looking words or phrases such as
"believe," "anticipate," and "planned," among others. These
forward-looking statements are based on Applera Corporation's current
expectations. The Private Securities Litigation Reform Act of 1995
provides a "safe harbor" for such forward-looking statements. In order
to comply with the terms of the safe harbor, Applera Corporation notes
that a variety of factors could cause actual results and experience to
differ materially from the anticipated results or other expectations
expressed in such forward-looking statements. The risks and
uncertainties that may affect the operations, performance, development,
and results of Applied Biosystems include but are not limited to: (1)
rapidly changing technology could adversely affect demand for Applied
Biosystems' products, and its business is dependent on development of
new products; (2)Applied Biosystems' sales are dependent on customers'
capital spending policies and government-sponsored research; and (3)
other factors that might be described from time to time in Applera
Corporation's filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release, and
Applera does not undertake any duty to update this information,
including any forward-looking statements, unless required by law.

For Research Use Only. Not for use in diagnostic procedures.

(C) 2005 Applera Corporation and MDS Inc. All Rights Reserved.

Applera is a trademark and Applied Biosystems is a registered trademark
of Applera Corporation or its subsidiaries in the U.S. and/or certain
other countries.

Q TRAP and QSTAR are registered trademarks of Applied Biosystems/MDS
SCIEX, a joint venture between Applera Corporation and MDS Inc.

-30-

Contact Information